Want to see KROS full AI Analyst Report?
Top Page
Keros Therapeutics
(NASDAQ:KROS)
Select Model
Select Model
Rating:50Neutral
Price Target:
$11.00
▼(-1.08% Downside)
Action:Reiterated
Date:09/09/26
The score is held down primarily by unstable fundamentals—strong 2025 results but a sharp deterioration in TTM with renewed losses and cash burn—despite a relatively solid low-leverage balance sheet. Technicals are modestly positive (price above key short/mid-term averages, positive MACD, neutral RSI), but valuation support is limited due to a negative P/E and no dividend yield data.
Positive Factors
Liquidity runway
The projected funding runway into the second half of 2028 gives Keros time to advance clinical programs without relying immediately on another financing. This supports strategic flexibility, reduces near-term dilution pressure, and provides greater capacity to absorb development setbacks.
Negative Factors
Unstable revenue base
The sharp reversal in revenue shows that recent earnings power is not yet durable and depends heavily on non-recurring or milestone-style payments. Such volatility makes operating performance difficult to forecast and leaves future funding needs sensitive to development timing.
Read all positive and negative factors
Positive Factors
Negative Factors
Liquidity runway
The projected funding runway into the second half of 2028 gives Keros time to advance clinical programs without relying immediately on another financing. This supports strategic flexibility, reduces near-term dilution pressure, and provides greater capacity to absorb development setbacks.
Read all positive factors
Keros Therapeutics (KROS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$224.44M
Dividend YieldN/A
Average Volume (3M)194.25K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth-93.55%
EPS Growth-1143.58%
CountryUS
Employees92
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.70
Shares Outstanding19,827,188
10 Day Avg. Volume157,517
30 Day Avg. Volume194,246
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.50
Price to Sales (P/S)3.11
P/FCF Ratio7.15
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$18.80Price Target Upside69.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-5.54
Revenue Forecast (FY)$16.37M
Keros Therapeutics Business Overview & Revenue Model
Company Description
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack...
How the Company Makes Money
Keros Therapeutics does not have product sales and, as a clinical-stage biotech, historically has generated limited revenue. Its revenue, when present, primarily comes from collaboration and license arrangements (e.g., upfront payments, research f...
Keros Therapeutics Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
72
Positive
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.01M | 244.06M | 3.55M | 151.00K | 0.00 | 20.10M |
| Gross Profit | 14.22M | 242.55M | 3.55M | 151.00K | 0.00 | 20.10M |
| EBITDA | -84.50M | 93.41M | -185.82M | -152.18M | -104.00M | -56.35M |
| Net Income | -83.16M | 87.01M | -187.35M | -152.99M | -104.68M | -58.74M |
Balance Sheet | ||||||
| Total Assets | 287.60M | 338.02M | 615.89M | 370.02M | 306.78M | 255.25M |
| Cash, Cash Equivalents and Short-Term Investments | 257.61M | 287.42M | 559.93M | 331.15M | 279.05M | 230.04M |
| Total Debt | 15.72M | 16.88M | 18.86M | 14.44M | 13.27M | 1.09M |
| Total Liabilities | 25.28M | 34.89M | 44.33M | 37.81M | 29.36M | 12.08M |
| Stockholders Equity | 262.32M | 303.13M | 571.55M | 332.21M | 277.42M | 243.17M |
Cash Flow | ||||||
| Free Cash Flow | -48.49M | 105.95M | -162.80M | -126.97M | -71.30M | -63.17M |
| Operating Cash Flow | -47.99M | 107.50M | -160.87M | -124.51M | -70.06M | -62.15M |
| Investing Cash Flow | -494.00K | -1.55M | -1.93M | -2.46M | -1.24M | -1.02M |
| Financing Cash Flow | -384.12M | -378.47M | 391.82M | 178.96M | 120.31M | 28.55M |
Keros Therapeutics Technical Analysis
Neutral
11.12
Price Trends
10.81
Positive
10.91
Positive
13.62
Negative
Market Momentum
0.16
Negative
53.51
Neutral
55.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KROS, the sentiment is Neutral. The current price of 11.12 is above the 20-day moving average (MA) of 10.98, above the 50-day MA of 10.81, and below the 200-day MA of 13.62, indicating a neutral trend. The MACD of 0.16 indicates Negative momentum. The RSI at 53.51 is Neutral, neither overbought nor oversold. The STOCH value of 55.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KROS.
Keros Therapeutics Risk Analysis
Keros Therapeutics disclosed 76 risk factors in its most recent earnings report. Keros Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Keros Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $727.39M | -36.05 | -15.77% | 642.31% | 16.83% | -494.61% | |
59 Neutral | $2.71B | -7.57 | -76.09% | ― | -58.40% | -31.99% | |
58 Neutral | $2.27B | -31.53 | -47.84% | ― | ― | ― | |
56 Neutral | $1.53B | -7.65 | -41.49% | ― | ― | -63.70% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $224.44M | -3.02 | -21.40% | ― | -93.55% | -1143.58% |
* Healthcare Sector Average
KROS
Keros Therapeutics
11.17
-4.54
-28.90%
GYRE
Gyre Therapeutics
7.17
-0.50
-6.52%
PVLA
Palvella Therapeutics
152.28
95.57
168.52%
NRIX
Nurix Therapeutics
26.13
16.93
184.02%
BCAX
Bicara Therapeutics Inc.
23.71
11.25
90.29%
Keros Therapeutics Corporate Events
Business Operations and StrategyStock BuybackFinancial Disclosures
Keros Therapeutics Announces Share Repurchase Authorization Program
Positive
Sep 8, 2026
On September 8, 2026, Keros Therapeutics announced that its board had authorized a $5 million share repurchase program for its common stock, to commence following receipt of a $20 million development milestone from Takeda Pharmaceuticals tied to f...
Business Operations and StrategyProduct-Related Announcements
Keros updates TGF-β pipeline strategy in new presentation
Positive
Aug 3, 2026
On August 3, 2026, Keros Therapeutics updated its corporate presentation for investors and analysts, detailing the development strategy for its TGF-β–modulating pipeline, led by rinvatercept (KER-065) and elritercept (KER-050), and high...
Business Operations and Strategy
Keros Therapeutics Earns Milestone Payment for Elritercept Trial
Positive
Jul 30, 2026
On July 30, 2026, Keros Therapeutics announced it will receive a $20 million development milestone payment from partner Takeda Pharmaceuticals under a global license agreement for elritercept. The payment was triggered by dosing the first patient ...
Executive/Board Changes
Keros Therapeutics Announces CFO Resignation and Interim Successor
Neutral
Jul 22, 2026
On July 17, 2026, Keros Therapeutics announced that Chief Financial Officer Keith Regnante resigned, effective August 3, 2026, to pursue other opportunities, with the board appointing Corporate Controller and Vice President, Finance, Annita Tanini...
Business Operations and StrategyExecutive/Board Changes
Keros Therapeutics Appoints Anne Prener to Board
Positive
Jun 25, 2026
On June 23, 2026, Keros Therapeutics’ board of directors appointed Anne Prener, M.D., Ph.D., as a Class III director, effective July 1, 2026, with a term running through the 2029 annual meeting. Keros announced the move publicly on June 25, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.